Isaac Francis - Author on Grafa
All
Rhythm Pharmaceuticals reports strong preliminary Q4 and FY 2025 IMCIVREE revenue growth
Boston-based Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, announced preliminary, unaudited net product revenues for its flagship therapy IMCIVREE (setmelanotide) for the fourth quarter and full year ended December 31, 2025.
Kroger unloads Vitacost to iHerb in push to streamline retail portfolio
The Kroger Company (NYSE:KR) completed the sale of its online health-and-wellness subsidiary, Vitacost.com, to iHerb on Friday, a move aimed at excising non-core digital assets as the grocery giant narrows its focus on its primary retail operations and high-return business lines.
ChipMOS rides AI memory wave to 20% revenue growth in Q4
ChipMOS TECHNOLOGIES (NASDAQ:IMOS) reported a sharp rise in fourth-quarter revenue on Friday, as the specialized semiconductor packager benefits from a "perfect storm" of high-density memory demand and a strategic shift toward AI-related infrastructure.
J&J strikes landmark deal with Trump administration to lower drug prices, avoid tariffs
Johnson & Johnson (NYSE:JNJ) became the latest pharmaceutical titan to bow to White House pressure, announcing a voluntary agreement to lower prescription drug costs in exchange for an exemption from the administration’s aggressive new import tariffs.







-640x358.jpg&w=1200&q=75)


-640x358.jpg&w=1200&q=75)